These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33073552)

  • 1. Repurposing of drugs for COVID-19: a systematic review and meta-analysis.
    Kotecha P; Light A; Checcucci E; Amparore D; Fiori C; Porpiglia F; Dasgupta P; Elhage O
    Panminerva Med; 2022 Mar; 64(1):96-114. PubMed ID: 33073552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
    Moneer O; Daly G; Skydel JJ; Nyhan K; Lurie P; Ross JS; Wallach JD
    BMJ; 2022 May; 377():e069400. PubMed ID: 35537738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
    Izcovich A; Siemieniuk RA; Bartoszko JJ; Ge L; Zeraatkar D; Kum E; Qasim A; Khamis AM; Rochwerg B; Agoritsas T; Chu DK; McLeod SL; Mustafa RA; Vandvik P; Brignardello-Petersen R
    BMJ Open; 2022 Mar; 12(3):e048502. PubMed ID: 35236729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatments for covid-19: living systematic review and network meta-analysis.
    Siemieniuk RA; Bartoszko JJ; Zeraatkar D; Kum E; Qasim A; Martinez JPD; Izcovich A; Lamontagne F; Han MA; Agarwal A; Agoritsas T; Azab M; Bravo G; Chu DK; Couban R; Devji T; Escamilla Z; Foroutan F; Gao Y; Ge L; Ghadimi M; Heels-Ansdell D; Honarmand K; Hou L; Ibrahim Q; Khamis A; Lam B; Mansilla C; Loeb M; Miroshnychenko A; Marcucci M; McLeod SL; Motaghi S; Murthy S; Mustafa RA; Pardo-Hernandez H; Rada G; Rizwan Y; Saadat P; Switzer C; Thabane L; Tomlinson G; Vandvik PO; Vernooij RW; Viteri-García A; Wang Y; Yao L; Zhao Y; Guyatt GH; Brignardello-Petersen R
    BMJ; 2020 Jul; 370():m2980. PubMed ID: 32732190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
    Baroutjian A; Sanchez C; Boneva D; McKenney M; Elkbuli A
    Am J Emerg Med; 2020 Nov; 38(11):2405-2415. PubMed ID: 33041111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
    Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
    Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs.
    Rodgers F; Pepperrell T; Keestra S; Pilkington V
    Trials; 2021 Jan; 22(1):59. PubMed ID: 33451350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial.
    Abayomi A; Osibogun A; Ezechi O; Wright K; Ola B; Ojo O; Kuyinu Y; Zamba E; Abdur-Razzaq H; Erinoso OA; Anya SE
    Trials; 2021 Dec; 22(1):869. PubMed ID: 34863267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
    Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
    Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.
    Yin G; Zhang C; Jin H
    JMIR Public Health Surveill; 2020 Jul; 6(3):e19538. PubMed ID: 32589146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
    Rodrigo C; Fernando SD; Rajapakse S
    Clin Microbiol Infect; 2020 Aug; 26(8):979-987. PubMed ID: 32470568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of COVID-19 drugs in a real clinical setting.
    Chiu MN; Bhardwaj M; Sah SP
    Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.